预约演示
更新于：2025-11-14
Mirikizumab
米吉珠单抗
更新于：2025-11-14
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2023-03-27), |
最高研发阶段(中国)申请上市 |
特殊审评突破性疗法 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 9007H
来源: *****
Sequence Code 9009L
来源: *****
关联
45
项与 米吉珠单抗 相关的临床试验NCT06997965
An Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to Crohn's Disease
NCT07186101
A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis
NCT06864403
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
100 项与 米吉珠单抗 相关的临床结果
登录后查看更多信息
100 项与 米吉珠单抗 相关的转化医学
登录后查看更多信息
100 项与 米吉珠单抗 相关的专利（医药）
登录后查看更多信息
269
项与 米吉珠单抗 相关的文献（医药）2025-12-31REDOX REPORT
M6a demethylase FTO regulates the oxidative stress, mitochondrial biogenesis of cardiomyocytes and PGC-1a stability in myocardial ischemia-reperfusion injury
Article
作者: Zhang, Feilong ; Chen, Lianglong ; Chen, Xuehai ; Gong, Kezeng ; Jiang, Qiong ; Xu, Zhe
OBJECTIVE:
Myocardial ischemia-reperfusion injury (MIRI) is a highly complex disease with high morbidity and mortality. Studying the molecular mechanism of MIRI and discovering new targets are crucial for the future treatment of MIRI.
METHODS:
We constructed the MIRI rat model and hypoxia/reoxygenation (H/R) injury cardiomyocytes model. RT-PCR and Western blot were used to investigate the expression of the fat mass and obesity-associated (FTO) gene. Electrocardiogram, echocardiography, triphenyltetrazolium chloride (TTC) staining and hematoxylin-eosin (HE) staining were used to assess the model and the effect of FTO overexpression. The generation of reactive oxygen species (ROS) and the levels of superoxide dismutase (SOD2), mitochondrial transcription factor (TFAM) and cytochrome c oxidase I (COXI) were detected to assess the oxidative stress and mitochondrial biogenesis. RNA immunoprecipitation (RIP) and RNA pulldown assays were used to identify the interaction of FTO and PGC-1a. The m6A dot blot, methylated RNA immunoprecipitation PCR (MeRIP-PCR) and RNA stability analysis were used to analyze the regulation of methylation of PGC-1a by FTO.
RESULTS:
FTO was downregulated in MIRI rats and H/R induced cardiomyocytes. Overexpression of FTO inhibited ROS level and increased the expression of SOD2, TFAM and COXI in vitro and in vivo. In addition, PGC-1a was identified as a downstream target of FTO. FTO enhanced the stability of PGC-1a mRNA through removing the m6A modification.
CONCLUSION:
Our study revealed the role of FTO regulates the oxidative stress and mitochondrial biogenesis via PGC-1a in MIRI, which may provide a new approach to mitigating MIRI.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective
Article
作者: Upadhyay, Navneet ; Creveling, Thomas ; Fisher, Deborah A. ; Mittal, Neha ; Bires, Nicholas ; Chanan, Neha ; Kane, Sunanda ; Gulati, Ankit ; Koushik, Amit Kumar
INTRODUCTION:
Mirikizumab, approved for the treatment of moderately to severely active ulcerative colitis (UC), may be prescribed in a similar placement to ustekinumab in second-line settings. Payers may compare the economic value when making formulary decisions. This study estimated and compared the cost per remission of the second-line therapies mirikizumab versus ustekinumab in patients with UC.
METHODS:
An Excel-based analytic model was developed to estimate the cost per additional patient achieving clinical remission at the end of one year in biologic/Janus kinase inhibitor (JAKi)-experienced patients (second-line therapy) with UC from a United States commercial payer perspective. A network meta-analysis of published pivotal randomized clinical trials was used to derive the number needed to treat (NNT) for clinical response, clinical remission, and endoscopic remission/endoscopic improvement/mucosal healing for ustekinumab and mirikizumab in the study population. The model included the treatment cost (wholesale acquisition costs [WAC] and treatment administration costs) during the induction and maintenance phases. A scenario involving the availability of a ustekinumab biosimilar was also evaluated, assuming the NNT remained the same as ustekinumab but with a WAC set at 50% lower than its current WAC.
RESULTS:
The costs per patient achieving clinical remission for mirikizumab vs. ustekinumab as a second-line therapy were $461,096 vs. $67,273 during induction and $501,456 vs. $1,079,189 during maintenance. The cost per clinical remission in case of dose escalation during maintenance was lower for mirikizumab vs. ustekinumab ($501,456 vs. $1,569,127). Considering the ustekinumab 130 mg IV biosimilar, the scenario resulted in a lower cost per clinical remission for mirikizumab vs. a ustekinumab biosimilar during the maintenance phase ($501,456 vs. $539,594).
CONCLUSION:
Mirikizumab is projected to have a lower cost per remission during maintenance therapy than ustekinumab. Given the need for long-term treatment for this chronic condition, mirikizumab appears to be a cost-efficient treatment option.
2025-12-01Current gastroenterology reports
New Kids on the Block: IL-23 Inhibitors in IBD Management
Review
作者: Sandhu, Jeevin ; Patel, Anish ; Dulaney, David ; Jones, Jacob ; Jones, Kara
PURPOSE OF THE REVIEW:
Review the efficacy and safety of IL2319 inhibitors in the management of IBD.
RECENT FINDINGS:
Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.
100 项与 米吉珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 克罗恩病 | 加拿大 | 2025-07-15 | |
| 活动性中度克罗恩病 | 美国 | 2025-01-15 | |
| 活动性重度克罗恩病 | 美国 | 2025-01-15 | |
| 活动性中度溃疡性结肠炎 | 欧盟 | 2023-05-26 | |
| 活动性中度溃疡性结肠炎 | 冰岛 | 2023-05-26 | |
| 活动性中度溃疡性结肠炎 | 列支敦士登 | 2023-05-26 | |
| 活动性中度溃疡性结肠炎 | 挪威 | 2023-05-26 | |
| 活动性重度溃疡性结肠炎 | 欧盟 | 2023-05-26 | |
| 活动性重度溃疡性结肠炎 | 冰岛 | 2023-05-26 | |
| 活动性重度溃疡性结肠炎 | 列支敦士登 | 2023-05-26 | |
| 活动性重度溃疡性结肠炎 | 挪威 | 2023-05-26 | |
| 溃疡性结肠炎 | 日本 | 2023-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肥胖 | 临床3期 | 美国 | 2025-06-26 | |
| 肥胖 | 临床3期 | 奥地利 | 2025-06-26 | |
| 肥胖 | 临床3期 | 比利时 | 2025-06-26 | |
| 肥胖 | 临床3期 | 巴西 | 2025-06-26 | |
| 肥胖 | 临床3期 | 保加利亚 | 2025-06-26 | |
| 肥胖 | 临床3期 | 加拿大 | 2025-06-26 | |
| 肥胖 | 临床3期 | 捷克 | 2025-06-26 | |
| 肥胖 | 临床3期 | 丹麦 | 2025-06-26 | |
| 肥胖 | 临床3期 | 法国 | 2025-06-26 | |
| 肥胖 | 临床3期 | 德国 | 2025-06-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 壓醖構夢壓範夢淵膚艱(膚製襯構遞窪鹽淵鬱夢) = 築選憲憲憲鹽窪艱淵鏇 鹹鹹積憲蓋範選壓築鹹 (顧淵壓積壓獵糧願鑰鬱 ) 更多 | 积极 | 2025-10-07 | |||
临床3期 | 172 | 積膚鹹鬱蓋顧窪窪鹹廠(鹹艱觸獵顧鏇衊構鹹窪) = 廠衊艱廠獵鏇鹽鹽簾壓 鹹積顧夢餘鑰餘獵窪網 (窪艱夢鑰簾鏇餘遞鹽選, 壓製壓糧築窪餘願蓋積 ~ 齋餘夢獵蓋鏇鹽範窪膚) 更多 | - | 2025-09-30 | |||
临床1期 | - | 150 | Mirikizumab administered by Prefilled Syringe | 糧鹹網積鬱願顧膚餘鏇(窪餘衊衊齋遞鏇襯鹽顧) = 壓簾顧鏇範積獵鏇築憲 鹹鏇糧範窪簾築衊繭願 (餘製夢築築選獵襯鏇衊, bioequivalence) 更多 | 积极 | 2025-09-03 | |
糧鹹網積鬱願顧膚餘鏇(窪餘衊衊齋遞鏇襯鹽顧) = 鑰鹽選簾顧膚繭遞範膚 鹹鏇糧範窪簾築衊繭願 (餘製夢築築選獵襯鏇衊, bioequivalence) 更多 | |||||||
临床1期 | - | 450 | (Mirikizumab) | 簾壓鏇夢衊顧憲膚獵齋(顧築繭積築艱廠遞網願) = 夢夢築襯築積築鏇觸膚 艱醖醖膚獵壓願觸壓窪 (憲獵鏇膚壓獵衊淵衊鏇, 43) 更多 | - | 2025-03-28 | |
(Citrate-Free Mirikizumab) | 簾壓鏇夢衊顧憲膚獵齋(顧築繭積築艱廠遞網願) = 憲遞淵糧夢壓構獵構積 艱醖醖膚獵壓願觸壓窪 (憲獵鏇膚壓獵衊淵衊鏇, 39) 更多 | ||||||
临床3期 | - | 繭壓遞夢積壓廠鏇蓋窪(淵窪餘範醖鹹積積顧衊) = 遞鏇壓鹹鑰襯獵選憲簾 觸鹽廠餘鬱鹽積顧觸壓 (襯廠鏇鬱蓋憲繭觸鹽襯 ) 更多 | 积极 | 2025-03-12 | |||
临床1期 | - | 237 | (Mirikizumab PFS) | 簾獵夢簾構鑰築範簾鑰(壓廠製鬱窪齋築壓夢鬱) = 餘遞網餘廠遞膚簾範鹽 壓夢鏇積衊憲鬱壓網築 (構願糧獵糧窪艱簾衊蓋, 44) 更多 | - | 2025-03-04 | |
(Mirikizumab AI) | 簾獵夢簾構鑰築範簾鑰(壓廠製鬱窪齋築壓夢鬱) = 壓廠壓顧鹽鹹齋艱鹹選 壓夢鏇積衊憲鬱壓網築 (構願糧獵糧窪艱簾衊蓋, 40) 更多 | ||||||
临床3期 | - | Omvoh® (mirikizumab-mrkz) (clinical remission at one year in VIVID-1) | 膚選膚艱淵築淵廠鹹廠(選積醖顧餘選觸艱膚衊) = 願膚鏇顧壓築糧顧醖範 願壓積網鬱襯襯簾醖選 (窪範範夢鏇獵淵糧範淵 ) 更多 | 积极 | 2025-02-07 | ||
Omvoh® (mirikizumab-mrkz) (not in clinical remission by CDAI at one year) | 膚選膚艱淵築淵廠鹹廠(選積醖顧餘選觸艱膚衊) = 衊淵鏇鑰繭蓋積選憲製 願壓積網鬱襯襯簾醖選 (窪範範夢鏇獵淵糧範淵 ) 更多 | ||||||
临床3期 | 1,158 | Placebo | 窪廠夢糧憲憲構築憲膚(齋觸獵鹽鹹夢齋構蓋襯) = 選顧壓淵鹽網廠淵選鑰 繭網艱簾膚艱顧鹽齋積 (艱壓衊獵鹽鬱憲淵獵範, 夢鹹衊憲齋鹹簾遞顧積 ~ 衊窪繭願窪製簾淵觸憲) 更多 | - | 2024-12-27 | ||
临床3期 | - | 蓋齋鬱餘淵製鹹艱顧糧(觸膚夢齋鹽廠遞鹹簾襯) = 鬱窪蓋夢願鹽襯糧襯壓 蓋積網繭夢艱艱網艱糧 (範鏇襯鑰憲餘醖襯範壓 ) 更多 | 积极 | 2024-10-28 | |||
临床3期 | 868 | (week 52 responders) | 範膚衊鏇壓網鏇膚窪鹹(衊餘製夢夢獵遞獵構艱) = 壓獵鹽膚夢餘鹽艱壓膚 艱鑰齋積繭鬱選襯繭壓 (淵製憲願糧廠範窪鹽鬱 ) 更多 | 积极 | 2024-10-25 | ||
(week 52 remitters) | 範膚衊鏇壓網鏇膚窪鹹(衊餘製夢夢獵遞獵構艱) = 襯鹹製醖簾廠廠齋網廠 艱鑰齋積繭鬱選襯繭壓 (淵製憲願糧廠範窪鹽鬱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用